Inventiva and Hepalys Pharma Enters into Exclusive Licensing Agreement to Develop and Commercialize Lanifibranor to Treat NASH in Japan and South Korea
Shots:
- Under the terms of the agreement, Inventiva will receive ~$10M up-front payment and ~$231M milestone payment along with tiered royalties while Hepalys will be responsible for conducting and financing all development trials in Japan and South Korea
- Inventiva also has the option to acquire the outstanding shares of Hepalys at a pre-agreed multiple of post-money valuation under certain conditions and has right of first refusal on receiving an offer to sell the license and rights related to lanifibranor
- Lanifibranor, is an oral PPAR agonist that acts by activating all three-peroxisome proliferator-activated receptor isoforms that regulate gene expression. It demonstrated a favorable tolerability profile and preclinical and clinical studies. Earlier, it received BTD and FTD from the US FDA
Ref: Inventiva | Image: Inventiva
Related News:- Inventiva Reports Investigator-Initiated P-II Trial Results of Lanifibranor for Type 2 Diabetes and Nonalcoholic Fatty Liver Disease
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
